The Argon Study: Investigational Treatment for Non-Alcoholic Steatohepatitis and Liver Fibrosis

Clinical Trial Title

A phase 2b randomized, double blind, placebo-controlled, multicenter study evaluating safety and efficacy of EDP-305 in subjects with liver-biopsy proven non-alcoholic steatohepatitis (NASH) (ARGON-2)

National Clinical Trial Number:

NCT04378010

Clinical Trial Protocol Description:

The purpose of this study is to test an experimental study drug called EDP-305. This study will test two different doses of the study medication compared to placebo (a “sugar pill”, an inactive substance that contains no medicine but looks exactly the same). The purpose of this study is to evaluate the effect of EDP-305 compared to placebo on liver fibrosis in NASH subjects with stage 2 or 3 fibrosis. Study participants and the study staff will not know whether they are receiving study drug or placebo.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria: 

  • Are between 18 and 75 years of age.
  • Have a diagnosis of NASH with Stage 2 or Stage 3 fibrosis.
  • Have no contraindications to MRIs.
  • Have a hemoglobin A1C < 9.5% .

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Sujit Janardhan, MD

Contact Information

Diana Goldman, RN